AC Immune is a biopharmaceutical company focusing on Alzheimer’s Disease (AD) drug development. The company develops innovative therapeutics with “best in class” potential against AD and other conformational diseases along three axes: vaccines, antibodies and small molecules. The therapeutics specifically target pathological conformations of the Abeta and Tau proteins and dissolve the plaques and tangles and/or inhibit their formation.
AC Immune´s clinical product pipeline consists of three clinical programs ACI-24, ACI.35 and crenezumab. The anti-Abeta vaccine ACI-24 and the anti-Tau vaccine ACI-35 are developed in-house and are in Phase I/IIa and Phase I clinical development respectively. The anti-Abeta monoclonal antibody crenezumab is developed by Genentech under an exclusive license agreement and is currently in Phase II clinical development. Additionally the antibody has been selected for the first groundbreaking Alzheimer's prevention trial. These clinical programs are backed by a rich portfolio of compounds at preclinical stage. The Diagnostic arm accelerates pre-clinical and clinical development and is pursuing two ways of detecting AD: IVD and PET.
AC Immune uses both an immunology and a chemistry platform technology to develop innovative therapies against conformational diseases. The immunological SupraAntigen™ Technology and the chemical Morphomer™ platform are designed to produce high affinity ligands, which bind specifically and with high-affinity to proteins in “sick” conformations.
The key advantages of the SupraAntigen™ platform are the highly selective mechanism of immune response, which is T-cell independent, and the unique specificity of the immune response. The technology can be used as the ultimate mimetics of pathological conformation of the antigen allowing rapid development of both vaccines and monoclonal antibodies even with weak immunogenic targets.
The Morphomer™ platform focuses the generation of conformation-specific small molecules with excellent biophysical properties for CNS compounds. The molecules are designed to selectively bind to aggregated amyolid targets and highly effectively solubilize Abeta-oligomers.